Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro
- PMID: 2578093
Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro
Abstract
Previous work by our laboratories demonstrated that dicoumarol can increase the enzymatic activation of mitomycin C (MC) to alkylating species by tumor cell sonicates under hypoxic conditions. To determine whether this increased generation of reactive metabolites would result in increased cytotoxicity, we examined the effect of this combination on the viability of EMT6 cells treated in vitro under hypoxic and oxygenated conditions. Dicoumarol increased the cytotoxicity of MC to these neoplastic cells under hypoxic conditions and decreased the toxicity of the antibiotic to aerobic cells. These findings suggested that dicoumarol might enhance the toxicity of MC to the hypoxic cells of solid tumors, without increasing the toxic side effects of the antibiotic to the host. Treatment of EMT6 tumor-bearing animals with both dicoumarol and MC significantly decreased the survival of the radioresistant hypoxic tumor cells from that obtained with MC alone. In contrast, the leukopenia produced by the antibiotic was not exacerbated by the addition of dicoumarol. These results suggest that a treatment regimen combining dicoumarol and MC might be a useful adjunct to radiation therapy for the eradication of the radioresistant hypoxic cells in solid tumors.
Similar articles
-
Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.Cancer Res. 1989 Jun 15;49(12):3310-3. Cancer Res. 1989. PMID: 2470504
-
Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns.Cancer Res. 1993 Nov 1;53(21):5127-34. Cancer Res. 1993. PMID: 7693331
-
Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.Cancer Res. 1984 Dec;44(12 Pt 1):5638-43. Cancer Res. 1984. PMID: 6437671
-
Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo.Anticancer Res. 1989 Jul-Aug;9(4):817-20. Anticancer Res. 1989. PMID: 2479329
-
Mitomycin C: a prototype bioreductive agent.Oncol Res. 1994;6(10-11):501-8. Oncol Res. 1994. PMID: 7620218 Review.
Cited by
-
Cellular pharmacology of quinone bioreductive alkylating agents.Cancer Metastasis Rev. 1993 Jun;12(2):165-76. doi: 10.1007/BF00689808. Cancer Metastasis Rev. 1993. PMID: 8375019 Review.
-
Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase.Cancer Chemother Pharmacol. 1988;22(2):126-30. doi: 10.1007/BF00257309. Cancer Chemother Pharmacol. 1988. PMID: 3136941
-
Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase.Jpn J Cancer Res. 1998 Sep;89(9):910-5. doi: 10.1111/j.1349-7006.1998.tb00648.x. Jpn J Cancer Res. 1998. PMID: 9818026 Free PMC article.
-
Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.Mol Pharmacol. 1996 Oct;50(4):728-35. Mol Pharmacol. 1996. PMID: 8863816 Free PMC article.
-
Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells.Cancer Chemother Pharmacol. 1993;33(3):215-20. doi: 10.1007/BF00686219. Cancer Chemother Pharmacol. 1993. PMID: 7505723
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources